BRD9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinoma
Abstract Background The intensive interplay between aberrant epigenetic events and metabolic remodeling represents one of the hallmarks of tumors, including colon cancer. The functions of Bromodomain Containing Protein BRD‐9 in colon cancer remains indefinite. We aimed to identify the biological rol...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.4954 |
| _version_ | 1811176426566582272 |
|---|---|
| author | Qunshan Zhu Xiang Gu Wei Wei Zheng Wu Fengqin Gong Xiaoqiang Dong |
| author_facet | Qunshan Zhu Xiang Gu Wei Wei Zheng Wu Fengqin Gong Xiaoqiang Dong |
| author_sort | Qunshan Zhu |
| collection | DOAJ |
| description | Abstract Background The intensive interplay between aberrant epigenetic events and metabolic remodeling represents one of the hallmarks of tumors, including colon cancer. The functions of Bromodomain Containing Protein BRD‐9 in colon cancer remains indefinite. We aimed to identify the biological roles and clinical significance of BRD9 in colon cancer. Methods The univariate‐ and multi‐variate Cox regression models were used to screen risk epigenetic regulators. Kaplan–Meier analysis and Pearson correlation analysis were used to assess clinical significance of BRD9. CCK‐8 assays, colony formation assay, Transwell, and soft‐agar assay were performed to determine the in vitro roles of BRD9. The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) of colon cancer cells were evaluated by a Seahorse XF Extracellular Flux Analyzer. In vivo models and RT‐qPCR, western blotting, and Chromatin Immunoprecipitation (ChIP) assay were conducted to explore the functional roles of BRD9 in COAD. Results In the study, we detected the expressions of 662 epigenetic regulators in COAD and identified a series of 42 hazard epigenetic factors with p < 0.05. Low‐throughput MTT assays highlighted that BRD9 is an essential target, and targeting BRD9 could reduce significant decreases of cell growth. BRD9 overexpression could notably elevate proliferation and migration potentialities, whereas, BRD9 ablation abolished these effects. Mechanistically, functional enrichment analysis indicated the potential associations between BRD9 and glycolysis metabolism. In addition, BRD9 epigenetically coordinates the H3K27ac modifications on the promoter regions of ENO2 and ALDOC, inducing enhanced glycolysis activity. Lastly, I‐BRD9 could significantly suppress the growth of colon cancer cells in vitro and in vivo. Conclusions Together, our study revealed previously unidentified roles of BRD9 in colon cancer metabolism and tumor progression, indicating that BRD9 could be a valuable therapeutic target for COAD patients. |
| first_indexed | 2024-04-10T19:51:19Z |
| format | Article |
| id | doaj.art-1022b074b2134869af2d8e2553e2b108 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-10T19:51:19Z |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-1022b074b2134869af2d8e2553e2b1082023-01-28T05:30:04ZengWileyCancer Medicine2045-76342023-01-011221572158710.1002/cam4.4954BRD9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinomaQunshan Zhu0Xiang Gu1Wei Wei2Zheng Wu3Fengqin Gong4Xiaoqiang Dong5Department of General Surgery The First Affiliated Hospital of Soochow University Suzhou ChinaDepartment of Radiotherapy Jiangdu People's Hospital Affiliated to Medical College of Yangzhou University Yangzhou ChinaDepartment of General Surgery Jiangdu People's Hospital Affiliated to Medical College of Yangzhou University Yangzhou ChinaDepartment of General Surgery Jiangdu People's Hospital Affiliated to Medical College of Yangzhou University Yangzhou ChinaDepartment of General Surgery Jiangdu People's Hospital Affiliated to Medical College of Yangzhou University Yangzhou ChinaDepartment of General Surgery The First Affiliated Hospital of Soochow University Suzhou ChinaAbstract Background The intensive interplay between aberrant epigenetic events and metabolic remodeling represents one of the hallmarks of tumors, including colon cancer. The functions of Bromodomain Containing Protein BRD‐9 in colon cancer remains indefinite. We aimed to identify the biological roles and clinical significance of BRD9 in colon cancer. Methods The univariate‐ and multi‐variate Cox regression models were used to screen risk epigenetic regulators. Kaplan–Meier analysis and Pearson correlation analysis were used to assess clinical significance of BRD9. CCK‐8 assays, colony formation assay, Transwell, and soft‐agar assay were performed to determine the in vitro roles of BRD9. The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) of colon cancer cells were evaluated by a Seahorse XF Extracellular Flux Analyzer. In vivo models and RT‐qPCR, western blotting, and Chromatin Immunoprecipitation (ChIP) assay were conducted to explore the functional roles of BRD9 in COAD. Results In the study, we detected the expressions of 662 epigenetic regulators in COAD and identified a series of 42 hazard epigenetic factors with p < 0.05. Low‐throughput MTT assays highlighted that BRD9 is an essential target, and targeting BRD9 could reduce significant decreases of cell growth. BRD9 overexpression could notably elevate proliferation and migration potentialities, whereas, BRD9 ablation abolished these effects. Mechanistically, functional enrichment analysis indicated the potential associations between BRD9 and glycolysis metabolism. In addition, BRD9 epigenetically coordinates the H3K27ac modifications on the promoter regions of ENO2 and ALDOC, inducing enhanced glycolysis activity. Lastly, I‐BRD9 could significantly suppress the growth of colon cancer cells in vitro and in vivo. Conclusions Together, our study revealed previously unidentified roles of BRD9 in colon cancer metabolism and tumor progression, indicating that BRD9 could be a valuable therapeutic target for COAD patients.https://doi.org/10.1002/cam4.4954BRD9colon cancerepigenetic modificationglycolysisI‐BRD9 |
| spellingShingle | Qunshan Zhu Xiang Gu Wei Wei Zheng Wu Fengqin Gong Xiaoqiang Dong BRD9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinoma Cancer Medicine BRD9 colon cancer epigenetic modification glycolysis I‐BRD9 |
| title | BRD9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinoma |
| title_full | BRD9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinoma |
| title_fullStr | BRD9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinoma |
| title_full_unstemmed | BRD9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinoma |
| title_short | BRD9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinoma |
| title_sort | brd9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinoma |
| topic | BRD9 colon cancer epigenetic modification glycolysis I‐BRD9 |
| url | https://doi.org/10.1002/cam4.4954 |
| work_keys_str_mv | AT qunshanzhu brd9isanessentialregulatorofglycolysisthatcreatesanepigeneticvulnerabilityincolonadenocarcinoma AT xianggu brd9isanessentialregulatorofglycolysisthatcreatesanepigeneticvulnerabilityincolonadenocarcinoma AT weiwei brd9isanessentialregulatorofglycolysisthatcreatesanepigeneticvulnerabilityincolonadenocarcinoma AT zhengwu brd9isanessentialregulatorofglycolysisthatcreatesanepigeneticvulnerabilityincolonadenocarcinoma AT fengqingong brd9isanessentialregulatorofglycolysisthatcreatesanepigeneticvulnerabilityincolonadenocarcinoma AT xiaoqiangdong brd9isanessentialregulatorofglycolysisthatcreatesanepigeneticvulnerabilityincolonadenocarcinoma |